36.39M shares outstanding
% Held by Insiders1: 37.58%
% Held by Institutions1: 8.70%
Shares Short (as of Mar 15, 2016)3: 978.18K
phase 3 CPX-351 drug for ML
only 25 employees making less than half of GERN`s
SP was $1.68 a month ago and $14+ now after their NEEDMOREHAM presentation. Needham initiated coverage on them
Their CEO doesn`t even race cars but he knows how to deliver when it comes to shareholders value
here we go again...Joko/Joanne_ de HI pretending to represent one side of the market. You switch to the dark side the minute you pump this to your set goal, which is a few cents higher before you take it all black.
Seriously no new data at those presentations and a rehash of known scientific research on IMET. Needmoreham!
"Trial 1951 Moving Along by irishtrader52 •Jan 11, 2016 9:03 AM" later removed
well then tell Chippy to use his 3% self appointed pay raise to buy shares directly on the open market. Tell him shareholders are not impressed with the 50% haircut his hedge fund buddies orchestrated in both Oct & again in Jan. which unlike 2014(INCY controlled FDA review committee's holddone ) was mainly on fear of a shelf registration and subsequent dilution.
you Joko/anne de hi say this to all the investors every time we precede a CC or presentation. How will or can those two presentations possibly impact the SP?
last years shelf registration and acquisition rumor was all that's needed to see what Chippy thinks of shareholder's investment value.
maybe after a decade he might be onto something....something that starts with S and rhymes with spam.
MF 1951 Mayo trials are already 3 years in the works as Irish you continually point out....yet no update from management?. Why?
" In April it will be 3 years since he(Jon) started the 1951 trial. He voluntarily left after 15 months(coinciding with the hold) and CR. He returned to the trial when he started to deteriorate - hemoglobin deteriorated fastest(and hold was lifted)"
That shows at least a year or three of durability and continued response however unlike your heading"on going MF Trials" suggests this trial is no longer recruiting and only previous patients are continually being treated....no expanded patient groups? WHY? Doesn't the IRB committee require a bigger sample group? Is MF like ET no longer a biggy? or do they already have enough data under orphan status to qualify? No update on this yet? WHY?
lets see now
1. we as shard holders still have no clue as to any indication of new trial developments wrt to CR or PR's
2. we still have no clue as to the collaborative agreement 's opt-in or out time frame
3. interim results won't be released to shareholders till 3RD Qrt or possibly 2017? or possibly worst case scenario, never?
4. huge burn rate down $48mil from previous Qrt. Hedgies have already priced that in.
5, no milestone payments from Janssen on the 2 new, already infusing IMET trials. IMBark, IMERGE and no update on the on going MF 1951 MAYO Clinic trial, cept for Chippy's Needmoreham reviewed version presentation.
might add that Dr T came to the rescue in lifting the FDA hold. Without his input Chippy would still be trying to punch his way out of that paper bag.
"support the fantastic job mgmt has done to shepherd IMET through FDA hold".... you mean sheep herd investors, no? We've experienced dilution in 2014 and face another with a registered shelf in 2015. What happened to the $48 mil more cash we had reported last Qrt? Too much compensation. And look at SP...dismal from even last year's $4.22 April 13, 2015 quote.
Oh shallow Ninja....and what is his interpretation for "foreseeable future", prey tell? All of 2015 he floated the acquisition idea for the entire year without acting on it other than to back up his intent with another shelf registration. That effectively killed SP for the entire 2015 year. Why acquired another 10,000 piece puzzle when you still have work to be done on the one you have sitting on the shelf? Not one GERON critic came out in support of such a move.
2014 was a write off albeit because of the FDA hold (may because of INCY's tentacles on the FDA review board or possibly our used car salesman just pull'n a fast one in buying more negotiating time for himself by not filing proper documentation concerning liver toxicity safety issues; we will never know) In retrospect GERON could never have pulled off any approval for IMET without someone else doing it for them. His race team maybe great at changing tires but biotech development seems beyond their capabilities. As far as MAYO Clinic's Imet experimental trials; the expanded US MF studies for summer of 2014 never happened as Irish the trader went on ad nauseam about; they in fact were scrapped by Janssen. The MAYO is not in the business of getting drugs approved by the FDA for sale, so yes we needed a more experienced heavyweight drug development partner. That deal I credit him for but seriously 2 years later and SP hasn't budged, now sitting exactly where it was when the collaborative agreement was inked with Janssen. Why? Only BM asks this question here. Are investors here that myopic?
Is he or fellow board members deserving of their significant annual compensation pkg? Give me $6 or $7 and i might change my mind.
2016 we never even experienced a proxy rally and the vol. of net shares being sold daily seems irregularly high. Will we soon find out he's pulled another shelf without fair warning?
and then there is the abscess like yourself rocky4 with your various handles like Joko, Joanie always waiting for that proverbial squeeze and SP erruption that hasn't happened in over 2 years now and through your various handles; cyst, boil, blister, sore, pustule, carbuncle, pimple, wen, whitlow, canker; inflammation & infection have caused any LT investor here only PAIN. We didn't even experience a proxy rally this year....explain that?